Agenus Analyst Ratings
B. Riley Adjusts Price Target on Agenus to $18 From $42, Maintains Buy Rating
Express News | Agenus Inc : B. Riley Cuts Target Price to $18 From $42
B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Cuts Target Price to $18
Agenus: Strong Clinical Potential Amidst Regulatory Challenges and Revised Market Entry Forecast
Agenus Appoints New Director and Plans Equity Offering
Agenus | 10-Q: Q2 2024 Earnings Report
Agenus Q2 2024 GAAP EPS $(2.52) Misses $(1.07) Estimate, Sales $23.509M Miss $61.477M Estimate
Earnings Flash (AGEN) AGENUS Reports Q2 Revenue $23.5M, Vs. Street Est of $63.5M
Express News | Agenus Reports Second Quarter 2024 Operational and Financial Results
Agenus Announces Appointment of Tom Harrison to Board of Directors
Agenus 2Q Loss/Shr $2.52 >AGEN
Here Is the Next Potential Market Catalyst
Agenus Q2 2024 Earnings Preview
Agenus Publishes Seminal Study on Botensilimab's Activity in Treatment-Resistant Cancers
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Bristol Ends Licensing Agreement With Agenus on TIGIT Bispecific Antibody
Express News | Agenus Inc - Bms Will Assign to Co All Regulatory Registrations, Applications, Authorizations, Approvals That Bms Holds in Connection With Agen1777
Express News | Agenus Inc - Will Have Right to Continue Development or Enter a Subsequent License in Future